logo-loader
viewMaxCyte Inc

Maxcyte licenses cell engineering technology to Nasdaq-listed Editas

Editas it is at the forefront of developing engineered cell medicines

MaxCyte Inc -

Maxcyte Inc’s (LON:MXCT) technology for engineered cell mechanisms is to be used by Nasdaq-listed genome specialist Editas Medicine for diseases such as sickle cell anaemia and blood disorders.

Through the non-exclusive deal, Editas has clinical and commercial rights to MaxCyte's Flow Electroporation and ExPert platforms to develop up to five therapies including four in immuno-oncology.

These include EDIT-301, an experimental Crispr medicine designed to durably treat sickle cell disease and blood illness beta-thalassemia.

In return, MaxCyte will receive development and approval milestones and sales-based payments alongside outside licensing fees. 

"We look forward to working with MaxCyte and using its leading technology to develop EDIT-301 as a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia, and for up to four engineered cell medicines to treat cancer," said Charles Albright, Editas’s chief scientific officer.

Editas is a US$1bn gene-editing company that uses the Crispr genome editing system to modify gene functions to tackle a range of diseases.

Doug Doerfler, MaxCyte’s chief executive, said Editas it is at the forefront of developing engineered cell medicines and he is excited to be working with such a pioneering business.

Maxcyte’s flow electroporation and ExPert technologies allow delivery of virtually any molecule, to any cell, at any scale with minimal disturbance to the cells.

Quick facts: MaxCyte Inc

Price: 107.2499 GBX

AIM:MXCT
Market: AIM
Market Cap: £61.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read